Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole M Verrills

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
The Journal of Clinical Investigation|August 25, 2007
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemiaPaolo Neviani, Ramasamy Santhanam, Joshua J Oaks, et al.
Clinical Proteomics|December 19, 2022
Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selectionDilana E Staudt, Heather C Murray, David A Skerrett-Byrne, et al.
Molecular Cancer Therapeutics|November 4, 2025
Discovery and characterisation of VPRBP/DCAF1 kinase inhibitor analogues as microtubular destabilising agents with potent anti-myeloma activityOlivia Susanto, Emily Gruber, Cheng Mun Wun, et al.
Science Signaling|March 28, 2023
Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapiesZacary P Germon, Jonathan R Sillar, Abdul Mannan, et al.
The Journal of Clinical Investigation|February 6, 2024
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine gliomaRyan J Duchatel, Evangeline R Jackson, Sarah G Parackal, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
The Journal of Clinical Investigation|August 25, 2007
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemiaPaolo Neviani, Ramasamy Santhanam, Joshua J Oaks, et al.
Clinical Proteomics|December 19, 2022
Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selectionDilana E Staudt, Heather C Murray, David A Skerrett-Byrne, et al.
Molecular Cancer Therapeutics|November 4, 2025
Discovery and characterisation of VPRBP/DCAF1 kinase inhibitor analogues as microtubular destabilising agents with potent anti-myeloma activityOlivia Susanto, Emily Gruber, Cheng Mun Wun, et al.
Science Signaling|March 28, 2023
Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapiesZacary P Germon, Jonathan R Sillar, Abdul Mannan, et al.
The Journal of Clinical Investigation|February 6, 2024
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine gliomaRyan J Duchatel, Evangeline R Jackson, Sarah G Parackal, et al.
Pageof 6